Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000094037

Apexbio Technology LLC Imeglimin hydrochloride 775351-61-6 100mg
SDP

Catalog No. 5000094037
Encompass_Preferred

Imeglimin hydrochloride (CAS 775351-61-6) is a small molecule investigated as an oral agent for type 2 diabetes It acts by modulating mitochondrial function across hepatic muscular and pancreatic tissues In hepatocytes imeglimin redirects substrate flow towards complex II inhibits complex I restores complex III activity and enhances fatty acid oxidation which is supported by increased 3-hydroxyacyl-CoA dehydrogenase activity and acylcarnitine levels The compound also reduces reactive oxygen species and elevates mitochondrial DNA content In high-fat high-sucrose diet mouse models imeglimin improves glucose tolerance insulin sensitivity and mitochondrial function while normalizing metabolic parameters Currently imeglimin is under clinical evaluation both as monotherapy and in combination with other antidiabetic agents

Catalog No. 50-000-94037 Supplier Apexbio Technology LLC Supplier No. B1067100
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Imeglimin hydrochloride (CAS 775351-61-6) is a small molecule investigated as an oral agent for type 2 diabetes It acts by modulating mitochondrial function across hepatic muscular and pancreatic tissues In hepatocytes imeglimin redirects substrate flow towards complex II inhibits complex I restores complex III activity and enhances fatty acid oxidation which is supported by increased 3-hydroxyacyl-CoA dehydrogenase activity and acylcarnitine levels The compound also reduces reactive oxygen species and elevates mitochondrial DNA content In high-fat high-sucrose diet mouse models imeglimin improves glucose tolerance insulin sensitivity and mitochondrial function while normalizing metabolic parameters Currently imeglimin is under clinical evaluation both as monotherapy and in combination with other antidiabetic agents

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.